Estuary Biotherapeutics Inc. emerged from stealth with a $93 million series A financing led by RA Capital Management to develop gene therapies to treat autosomal dominant polycystic kidney disease ...
Life sciences investors are raising billions of dollars in fresh capital, with a cluster of new funds and acquisition vehicles positioning specialist firms for more biotech company formation and ...
Biopharma deals, excluding M&As, reached $224.91 billion in the first nine months of 2026, up 5% from $213.62 billion during the same period in 2025. The year-to-date total was the highest in BioWorld ...
T cells as potent killers of small-cell lung cancer, with their genetic signature potentially revealing patients who could ...
Following ongoing deals with Bristol Myers Squibb Co. and Eli Lilly and Co., AI and machine learning firm Insitro Inc. has ...
The U.S. FDA accepted Zydus Lifesciences Ltd. and Formycon AG’s BLA for FYB-206, a proposed biosimilar to Keytruda ...
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that limits T-cell activity and enables tumors to ...
An observational study of 70,257 U.S. patients with both schizophrenia and type 2 diabetes has added weight to the emerging ...
Just in time for the flu season, Sanofi SA has reached an agreement to resolve the EU Commission’s preliminary concerns about ...
In line with expectations, Iambic Therapeutics Inc. went public Oct. 15, pricing its IPO of 9.375 million shares at $16 apiece for gross proceeds of about $150 million. Another $22.5 million could ...
Altay Therapeutics Inc. has completed a $37 million series A financing as it advances development of novel small-molecule transcription factor inhibitors.
The multinational pharma industry is pushing back against Japan’s proposed expansion of drug price reductions, warning that increasingly complex reimbursement policies could undermine efforts to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results